PTCT Q4 2021 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$165M+39.0% YoY

Gross Profit

$156M94.4% margin

Operating Income

-$85M-51.3% margin

Net Income

-$143M-86.7% margin

EPS (Diluted)

$-2.03

QoQ Revenue Growth

+19.1%

Cash Flow

Operating Cash Flow

-$69M

Free Cash Flow

-$93M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$1.9B

Stockholders' Equity

$1M

Cash & Equivalents

$190M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$165M	$119M	+39.0%
Gross Profit	$156M	$114M	+36.8%
Operating Income	-$85M	-$96M	+12.1%
Net Income	-$143M	-$74M	-92.7%

Geographic Segments

Non-US

$70M59%

United States

$48M41%